Hillert, Jan published the artcileA comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry, Related Products of esters-buliding-blocks, the publication is Multiple Sclerosis Journal (2022), 28(2), 237-246, database is CAplus and MEDLINE.
Teriflunomide and di-Me fumarate (DMF) are first-line disease-modifying treatments for multiple sclerosis with similar labels that are used in comparable populations. The objective of this study was to compare the effectiveness and persistence of teriflunomide and DMF in a Swedish real-world setting. All relapsing-remitting multiple sclerosis (RRMS) patients in the Swedish MS registry initiating teriflunomide or DMF were included in the anal. The primary endpoint was treatment persistence. Propensity score matching was used to adjust comparisons for baseline confounders. A total of 353 teriflunomide patients were successfully matched to 353 DMF. There was no difference in the rate of overall treatment discontinuation by treatment group across the entire observation period (hazard ratio (HR) = 1.12; 95% confidence interval (CI) = 0.91-1.39; p = 0.277; reference = teriflunomide). Annualised relapse rate (ARR) was comparable (p = 0.237) between DMF (0.07; 95% CI = 0.05-0.10) and teriflunomide (0.09; 95% CI = 0.07-0.12). There was no difference in time to first on-treatment relapse (HR = 0.78; 95% CI = 0.50-1.21), disability progression (HR = 0.55; 95% CI = 0.27-1.12) or confirmed improvement (HR = 1.17; 95% CI = 0.57-2.36). This population-based real-world study reports similarities in treatment persistence, clin. effectiveness and quality of life outcomes between teriflunomide and di-Me fumarate.
Multiple Sclerosis Journal published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C6H8O4, Related Products of esters-buliding-blocks.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics